Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Latin America Health Times.
Press releases published on June 6, 2025
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
·
June 6, 2025
DALLAS, June 06, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the …
Spur Therapeutics Presents Positive New Preclinical Data on Its Gene Therapy Candidate for GBA1 Parkinson’s Disease at 2025 GBA1 Meeting
GlobeNewswire
·
June 6, 2025
Data show SPR301 lowered α-synuclein, a hallmark of Parkinson’s disease, in cellular models, indicating potential for efficacy at doses with favorable safety Demonstrated greater α-synuclein reductions compared to other gene therapy approaches LONDON, June …
Arcutis to Present New Long-Term Results of ZORYVE® (roflumilast) Cream at the 2025 Revolutionizing Atopic Dermatitis Conference
GlobeNewswire
·
June 6, 2025
New data from the Phase 3 INTEGUMENT-OLE long-term open label study show durable improvement in the signs and symptoms of atopic dermatitis (AD), including almost half of participants achieving no or minimal itch with ZORYVE cream 0.15% or ZORYVE cream 0. …
PetVivo and Commonwealth Partner to Advance Equine Wellness Across Thoroughbred Racing
GlobeNewswire
·
June 6, 2025
Minneapolis, MN, June 06, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV; OTCPINK: PETVW), an emerging biomedical device company focused on animal health, today announced a strategic collaboration with Commonwealth, the syndicated ownership …
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
·
June 6, 2025
SAN DIEGO, June 06, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on June …
TG Therapeutics to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
GlobeNewswire
·
June 6, 2025
NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in the Goldman Sachs 46th Annual Global Healthcare Conference, …
Venus Concept Announces Definitive Agreement to Sell Venus Hair Business for $20 Million
GlobeNewswire
·
June 6, 2025
TORONTO, June 06, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced today it has entered into a definitive agreement to sell its Venus Hair business to MHG …
Arvinas Announces Submission of New Drug Application to U.S. FDA for Vepdegestrant for Patients with ESR1-Mutated ER+/HER2- Advanced or Metastatic Breast Cancer
GlobeNewswire
·
June 6, 2025
– This submission is supported by the pivotal Phase 3 VERITAC-2 clinical trial, results of which were recently presented at the 2025 American Society for Clinical Oncology Annual Meeting and published in The New England Journal of Medicine – – VERITAC-2 …
BioCryst Achieves Reimbursement for ORLADEYO Across all Major European Countries
GlobeNewswire
·
June 6, 2025
RESEARCH TRIANGLE PARK, N.C., June 06, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that, following a positive recommendation from the Zorginstituut Nederland, ORLADEYO® (berotralstat) has been approved for the …
ProPhase Labs Announces Formation of Clinical Science Advisory Board to Accelerate Commercialization of BE-SmartTM Esophageal Disease Diagnostic Platform
GlobeNewswire
·
June 6, 2025
UNIONDALE, NY, June 06, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ: PRPH), (the “Company” or “ProPhase”) a next generation biotech, genomics and consumer products company, today announced the formation of its Clinical Science Advisory Board to …
Denovo Biopharma Announces Formation of Neuroscience Scientific Advisory Board to Advance Precision Medicine in Depression
GlobeNewswire
·
June 6, 2025
- Scientific Advisory Board brings together distinguished experts in neuroscience to support Denovo’s CNS development programs, including the Phase 3-ready lead program, biomarker-guided DB104 (liafensine) in treatment-resistant depression (TRD) - SAN …
Nurix Therapeutics to Host a Webcast Conference Call to Discuss Data from the Ongoing Phase 1 Clinical Trial of Bexobrutideg (NX-5948) Being Presented at the 30th European Hematology Association Congress (EHA2025)
GlobeNewswire
·
June 6, 2025
SAN FRANCISCO, June 06, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that …
Rectify Pharma Presents Translational Data Demonstrating Improvements in Kidney Function and Reductions in Vascular Calcification at ERA 2025
GlobeNewswire
·
June 6, 2025
Potent, selective ABCC6-targeting positive functional modulator (PFM) improved multiple markers of renal function in animal models of chronic kidney disease (CKD) PFM improved inorganic pyrophosphate (PPi) efflux via on-target engagement of the ABCC6 …
Polpharma Group soutient l’action urgente de l’UE visant à garantir l’accès aux médicaments et à renforcer la souveraineté pharmaceutique européenne
GlobeNewswire
·
June 6, 2025
AMSTERDAM, 06 juin 2025 (GLOBE NEWSWIRE) -- Polpharma Group, fabricant européen de produits pharmaceutiques de premier plan, s’est joint aux autres membres de l’association Medicines for Europe pour signer une lettre ouverte adressée aux Premiers ministres …
Die Polpharma Group unterstützt dringende Maßnahmen der EU zur Sicherung des Zugangs zu Arzneimitteln und zur Stärkung der pharmazeutischen Souveränität Europas
GlobeNewswire
·
June 6, 2025
AMSTERDAM, June 06, 2025 (GLOBE NEWSWIRE) -- Die Polpharma Group, ein führender europäischer Pharmahersteller, hat sich anderen Mitgliedern von Medicines for Europe angeschlossen und einen offenen Brief an die Premierminister und Gesundheitsminister aller …
Burning Rock Reports First Quarter 2025 Financial Results
GlobeNewswire
·
June 6, 2025
GUANGZHOU, China, June 06, 2025 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today …
OBI Pharma Enters ADC Collaboration with TegMine Therapeutics utilizing GlycOBI® and TegMiner™ Enabling Technologies
GlobeNewswire
·
June 6, 2025
TAIPEI, Taiwan, June 06, 2025 (GLOBE NEWSWIRE) -- OBI Pharma, Inc. (OBI), a clinical-stage global oncology company specialized in the development of novel cancer therapies such as antibody-drug conjugates (ADCs) (4174. TWO), and TegMine Therapeutics, Inc. …
浩鼎自创ADC平台GlycOBI® 首宗技术合作案 携手美国TegMine开发ADC
GlobeNewswire
·
June 6, 2025
台湾, June 06, 2025 (GLOBE NEWSWIRE) -- 浩鼎生技（以下简称「浩鼎」）（4174.TWO）今（06/06）宣布，与美国TegMine Therapeutics, Inc.（以下简称「TegMine」）签署ADC研发服务合约（Master Services Agreement, MSA）；TegMine 是一家总部位于美国旧金山的生物制药公司，专注于开发针对癌症相关糖蛋白的创新抗体疗法。浩鼎则致力于开发抗癌新药及聚焦研发次世代抗体药物复合体（ADCs）。 根据合约，浩鼎将与 …
浩鼎自創ADC平台GlycOBI® 首宗技術合作案 攜手美國TegMine開發ADC
GlobeNewswire
·
June 6, 2025
台灣, June 06, 2025 (GLOBE NEWSWIRE) -- 浩鼎生技（以下簡稱「浩鼎」）（4174.TWO）今（06/06）宣布，與美國TegMine Therapeutics, Inc.（以下簡稱「TegMine」）簽署ADC研發服務合約（Master Services Agreement, MSA）；TegMine 是一家總部位於美國舊金山的生物製藥公司，專注於開發針對癌症相關醣蛋白的創新抗體療法。浩鼎則致力於開發抗癌新藥及聚焦研發次世代抗體藥物複合體（ADCs）。 根據合約，浩鼎將與 …
Addex GABAB PAM Candidate Demonstrates Robust Anti-Tussive Activity in Multiple Chronic Cough Preclinical Models
GlobeNewswire
·
June 6, 2025
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, June 6, 2025 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for …